Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
THE IMPACT OF DIABETES AND OBESITY ON ARTERIAL HYPERTENSION
Mavlonov Namoz Xalimovich
Associate Professor, Department of Internal Medicine in Family Medicine, Bukhara State
Medical Institute named after Abu Ali Ibn Sina, PhD
ORCID ID: 0000-0003-0348-9860
Abstract:
Type 2 diabetes and obesity are among the most pressing global public health
concerns today. Both conditions play a significant role in the development of arterial
hypertension and significantly increase the risk of cardiovascular diseases. This article
discusses the role of diabetes and obesity in the pathogenesis of hypertension, their
interrelation, and modern therapeutic approaches.
Keywords:
arterial hypertension, diabetes mellitus, obesity, insulin resistance,
cardiovascular risk
Introduction
Arterial hypertension (AH) is one of the main risk factors for cardiovascular diseases, and its
development is influenced by numerous metabolic factors. Among these, diabetes mellitus
and obesity are considered the most crucial. According to statistics, 60–80% of patients with
type 2 diabetes also suffer from hypertension. Likewise, individuals with excessive div
weight are 2–3 times more likely to develop hypertension compared to those with normal
weight.
Recent Research and New Approaches
1.
Gut Microbiota and Hypertension Connection
Recent studies have shown that
imbalances in the gut microbiota (dysbiosis)
play a
significant role in the development of hypertension. In patients with diabetes and obesity,
alterations in the gut flora lead to increased inflammatory processes, which directly affect
vascular tone and blood pressure regulation.
2.
A New Perspective on Visceral Fat Tissue
In recent years,
visceral fat tissue
has been redefined not just as a passive fat storage site,
but as an
active endocrine organ
. This tissue secretes hormones and mediators such as
leptin
,
resistin
,
TNF-α
, and
IL-6
, which negatively impact the cardiovascular system.
Particularly,
leptin resistance
plays a key role in the pathogenesis of chronic hypertension
in obese individuals.
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
3.
SGLT-2 Inhibitors – A New Era in Treatment
Sodium-glucose co-transporter 2 (SGLT-2) inhibitors, such as
dapagliflozin
, used in the
treatment of diabetes, not only lower blood glucose levels but also
reduce blood pressure
by promoting diuresis and helping prevent heart failure. These drugs provide
dual benefits
in managing both diabetes and hypertension.
Relationship Between Diabetes and Arterial Hypertension
Type 2 diabetes significantly contributes to the development of arterial hypertension through
the following mechanisms:
Insulin resistance:
This condition disrupts endothelial function, reducing the production of
nitric oxide (NO), a vasodilator. Consequently, blood vessels fail to dilate properly, leading
to increased vascular tone and elevated blood pressure.
Hyperinsulinemia:
Excess insulin in the blood enhances renal sodium reabsorption, leading
to fluid retention and increased blood volume, which in turn elevates blood pressure.
Advanced glycation end products (AGEs):
These molecules damage the vascular walls,
promoting atherosclerosis and hypertension.
The Impact of Obesity on Arterial Hypertension
Obesity, especially central (abdominal) obesity, has a direct impact on blood pressure
regulation:
Imbalance in adipokines:
Increased leptin and decreased adiponectin levels influence
vascular tone. Leptin activates the sympathetic nervous system, leading to tachycardia and
vasoconstriction.
Proinflammatory markers:
In obesity, the levels of cytokines such as interleukin-6 (IL-6)
and tumor necrosis factor-alpha (TNF-α) are elevated, which enhances vascular
inflammation and contributes to persistent hypertension.
Increased blood volume:
Excess div weight places additional workload on the heart,
increasing cardiac output and blood pressure.
Pathogenetic Scheme
Pathogenetic factor Mechanism of action
Insulin resistance
Endothelial dysfunction → vasoconstriction → hypertension
Leptin excess
Activation of sympathetic nervous system → increased heart rate and
vasoconstriction
Adiponectin
deficiency
Loss of vascular protective effects
Renal
sodium Increased blood volume → elevated blood pressure
Vo
lu
m
e
5,
Ju
ne
,2
02
5
,
M
ED
IC
AL
SC
IE
N
CE
S.
IM
PA
CT
FA
CT
OR
:7
,8
9
Pathogenetic factor Mechanism of action
retention
Prevention and Treatment Approaches
A. Lifestyle modifications:
Weight reduction (target BMI <25 kg/m²)
Low-salt, balanced diet
Regular physical activity (at least 150 minutes/week of aerobic exercise)
B. Pharmacotherapy:
Antihypertensive therapy:
ACE inhibitors, ARBs, diuretics
Diabetes management:
Metformin, SGLT-2 inhibitors, GLP-1 receptor agonists
Lipid control:
Statins
Anti-obesity therapy:
Orlistat, GLP-1 receptor agonists (if BMI >30)
Conclusion
Diabetes mellitus and obesity are major contributors to the development and progression of
arterial hypertension. Their interconnected pathogenic mechanisms exacerbate hypertension
and increase the risk of cardiovascular complications. Early diagnosis, comprehensive
treatment, and promoting a healthy lifestyle are key strategies in preventing and managing
these conditions.
References
(APA Style)
1. Whelton, P. K., Carey, R. M., Aronow, W. S., et al. (2018). 2017
ACC/AHA/AAPA/ABC/ACPM/AGS/ APhA/ASH/ASPC/NMA/PCNA Guideline for
the Prevention, Detection, Evaluation, and Management of High Blood Pressure in
Adults.
Hypertension
,
71(6),
e13–e115.
https://doi.org/10.1161/HYP.0000000000000065
2. Grundy, S. M. (2016). Metabolic syndrome update.
Trends in Cardiovascular Medicine
,
26(4), 364–373. https://doi.org/10.1016/j.tcm.2015.10.004
3. Alberti, K. G., Zimmet, P., & Shaw, J. (2005). The metabolic syndrome—a new
worldwide definition.
The Lancet
, 366(9491), 1059–1062.
4. Reaven, G. M. (1988). Banting lecture 1988. Role of insulin resistance in human disease.
Diabetes
, 37(12), 1595–1607.
UpToDate. (2024). Pathogenesis and treatment of hypertension in diabetes mellitus.
